Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics for the treatment of genetically defined diseases.
No data available for ALNYLAM PHARMACEUTICALS INC. Target value per method: min. 100%
Greenhouse Gas Emissions
ALNYLAM PHARMACEUTICALS INC emits 1,2 times its CO₂ budget of 11,751 tons of CO₂ equivalent. Target value per method: max. 100% of CO₂ budget
Supply Chain
Taking into account the entire supply chain, ALNYLAM PHARMACEUTICALS INC emits 14,8 times its CO₂ budget of 11,751 tons of CO₂ equivalent. Target value per method: max. 100% of CO₂ budget
Recycling and Recovery of Waste
No data available for ALNYLAM PHARMACEUTICALS INC. Target value per method: min. 75%
Society
64%
Union Formation and Collective Bargaining Power
No data available for ALNYLAM PHARMACEUTICALS INC. Target value per method: min. 80%
CEO Pay Ratio
CEO Yvonne Greenstreet earns 39 times the median salary of employees. Target value per method: max. 30 times
Employee Turnover Rate
ALNYLAM PHARMACEUTICALS INC has an employee turnover rate of 12,6%. Target value per method: max. 10%
Harassment and Discrimination at the Workplace
ALNYLAM PHARMACEUTICALS INC meets 4 quality criteria for handling harassment and discrimination at the workplace. Target value per method: 4 quality criteria
Gender
68%
Women on Board
ALNYLAM PHARMACEUTICALS INC has 36,4% women across its top leadership and supervisory bodies. Target value per method: min. 40%
Gender Pay Gap
No data available for ALNYLAM PHARMACEUTICALS INC. Target value per method: max. 3%
Women in Management
ALNYLAM PHARMACEUTICALS INC employs 40% female managers. Target value per method: min. 40%
Glass Ceiling
The proportion of women in senior management at ALNYLAM PHARMACEUTICALS INC is 71,4% of the proportion of women in the overall workforce. Target value per method: min. 90%
Sustainable [100]
Almost sustainable [67-99]
Moderate [34-66]
Not sustainable [0-33]
No data
Renewable Energy
No data available for ALNYLAM PHARMACEUTICALS INC. Target value per method: min. 100%
Greenhouse Gas Emissions
ALNYLAM PHARMACEUTICALS INC emits 1,2 times its CO₂ budget of 11,751 tons of CO₂ equivalent. Target value per method: max. 100% of CO₂ budget
Supply Chain
Taking into account the entire supply chain, ALNYLAM PHARMACEUTICALS INC emits 14,8 times its CO₂ budget of 11,751 tons of CO₂ equivalent. Target value per method: max. 100% of CO₂ budget
Waste Recycling
No data available for ALNYLAM PHARMACEUTICALS INC. Target value per method: min. 75%
Sustainable [100]
Almost sustainable [67-99]
Moderate [34-66]
Not sustainable [0-33]
No data
We measure the sustainability of companies based on 12 criteria.Indicators range from 0 to 100: values from 0 to 33 are shown in red (“not sustainable”), values from 34 to 66 in yellow (“moderate”), values from 67 to 99 in light green (“almost sustainable”), and a value of 100 in green (“sustainable”). Learn more about our method.
Look at that!
I checked the impact of this company
ALNYLAM PHARMACEUTICALS INC
US02043Q1076
Sustainable [100]
Almost sustainable [67-99]
Moderate [34-66]
Not sustainable [0-33]
powered by
www.moneycare.io
Compare ALNYLAM PHARMACEUTICALS INC with ...
ALNYLAM PHARMACEUTICALS INC
?
Impact Score
Climate
Society
Gender
24%
64%
68%
0%
0%
0%
ALNYLAM PHARMACEUTICALS INC
?
Impact Score
Climate
Renewable Energy
—
Greenhouse Gas Emissions
87%
Supply Chain
7%
Waste Recycling
—
Society
Collective Agreements
—
CEO Pay Ratio
77%
Employee Turnover Rate
80%
Anti-Discrimination
100%
Gender
Women on Board
91%
Gender Pay Gap
—
Women in Management
100%
Glass Ceiling
79%
Sources of sustainability performance
Metric
Value
Unit
Year
PDF Name
PDF Page
No sources found.
Note: The PDF pages given here refer to the page in the PDF document, which is not necessarily the one found in the footer of the page. For example, page 10 is the 10th page in the document, even if it is labeled as page 8.